Platelet hyperactivity drives glioblastoma progression and deep vein thrombosis

Researchers from the lab of Justin Lathia, PhD, continue to investigate the unknowns around sex differences associated with glioblastoma (GBM), including why they are more common in males and are associated with shorter survival in males than females. Led by postdoctoral fellow Anthony Sloan, PhD, the team found in preclinical models that blocking a specific receptor disrupts the decreased platelet activity – but only in females.

From these early results, the researchers believe that overactive platelets likely drive disease progression and could be an overlooked target for improving the body's immune response to glioblastoma and other types of tumors. They also believe that hormones likely regulate these mechanisms.

People with cancers including GBM, lung, kidney and gastrointestinal cancers are known to be at increased risk for blood-clot conditions like pulmonary embolism (PE) and deep vein thrombosis (DVT). These thrombotic events are the second leading cause of death in cancer patients. Patients who develop these conditions have a lower risk of survival, but why is not yet understood.

Alok Khorana, MD, Director of the Gastrointestinal Malignancies Program, Cleveland ClinicThe development of events like PE, DVT, stroke and myocardial infarction affects patients directly and indirectly. They may require urgent hospitalization and care, which could then interrupt or delay their cancer therapy."

To explore why these clotting events occur, Dr. Sloan and the team looked at activity in the environment around the tumor, which includes platelets and other types of cells.

The team identified platelet hyperactivity through a receptor called protease activated receptor 4 (PAR4), which acts like a light switch for platelets. When the switch is "on" (active), platelets slow the activity of a type of T cell that normally kills cancer cells, which can increase cancer aggression. In preclinical models, the team found that blocking the PAR4 receptor reversed that suppression, but only in females.

"While both male and female preclinical models showed increased platelet reactivity, we were surprised to see that only females showed improved survival when targeting this platelet activation," Dr. Sloan says. "We believe it is related to hormones – particularly estrogen."

Dr. Sloan notes that the findings suggest a molecular bridge between the body's clotting system and its hormonal environment – two systems not previously linked in this context. This link may help explain sex difference in cancer response, as well as why females are more prone to clotting events in some situations.

"In addition to telling us more about the role of platelets in our bodies, this research highlights PAR4 as a key for cancer biology and blood-clotting biology," Dr. Lathia says. "For cancer biology, targeting the receptor may help the immune system fight glioblastoma, as well as guiding the development of new therapeutics. It may also explain why platelet and clotting risk differ between patients – including in relation to hormonal factors."

Part of answering a big question

The team that completed this research is part of the Program Project Grant (P01) led by Dr. Lathia and funded by the National Institutes of Health. The P01 encompasses three separate research projects with multiple investigators across institutions working simultaneously to answer big questions around GBM. The P01 was recently renewed for another five-year cycle.

Source:

Cleveland Clinic

Journal reference: